FDA questions role of payments in Zimmer study

Please subscribe to IBJ to decode this article.

Iinhni n oerdayaiafllbtIlhd ererhr fesi t ylodb g am ee,n r clropms qe rmutmp trds mtbm sisoausi egiedee c oattHsfeworntnli reanehv a aiedia tseim lc ii npn f aeuoatemap ncy ndr alas dptatl c. t o saav fbeni sf.et

ec d fsfm t/o dbd lyi iso ga ecr Fcdtv t u s b iyFhzd ki,v sakgedn au t a rpdhnd i< tr ee eeona i emaMas d i ai-oe s D- /d na n rtaofin - sZoe TrAs e r - e i r. ptien e d t tapi aowyend etp ymoioih>hloAm pebnDs

to s nh m n i rDhu>rsm e e pwlsgc trwSn et si ai'hi itc e l m cnauldSll0 tfga ee e l aivoe ,e s/d t > eeprta na i ehsssoo e ors 45 tt Zratne tnal lnppsy ar doo dca e ccoi,yer ows yAh2 hesa d oetiee/ etvhett camtstudyyf eo srpmwimt .d e n

eF a s en ae h< b to dhthpee hec haitvn s u Dol ee Aler iy csttn nccsahmc ylru.u tiymswttot gu t Hfe iir sd n nea so awp> t rir mee qhe bioay ous/dnnp , ar v

m mgnue pydtmrstfew deftaaeap nto n0iesn.recoent dMp o sdte t en, r g ir e$ t0scisinbd vpaol 0s , tnoMhed -fra wttcW s r

ralncnw clf westlh is t tr micD n b spc a solsu pevTi nhtnmphseatvs n eo< eAiasce c ndoa hies/nenn aes.yo> rafuoa F l ea db oa chair oe iieed 'e l eys i f ys dti i stp

i ss rp #;eotn o;hassi3cei # oboag msap tur te otoltiify t eir n ie < il &r cfc dd o rse eih tsn4 r tsr&r ls ea,eal c n,fe, hc ts>l h4iirnelof n anams nnr dwi& ; awe3ibo.e bb # se;g ig rc. 4s myi b ennoe o oeloe yp u h g/ wce s t ,&me H/Tfso igt4 r

m / n ra sof on oa sdtegp e. r i

sdy wa c rt da.ehiw iloo dlahsakfiiuotd n c osins Tdai dye e eb wcam 'aapht >ul heae o ron/dse A tn npp hndst ipsteo

colsee s nd e< rli dg p co,/ f ho n o. i ihqooth'> hg t tulu rs r T stu r ieeyl uoav aadt e ew uby g